SCHEMBL4054476

SCHEMBL4054476

Fc1ccccc1-c1ccc2nc(-c3ccccc3)oc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VSIR Q9H7M9 1/20 0.61
HDAC3 O15379 1/20 0.53
HDAC1 Q13547 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
GPR119 Q8TDV5 10/20 0.52
MAPT P10636 3/20 0.51
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
MEN1 O00255 2/20 0.51
ALDH1A1 P00352 2/20 0.51
KMT2A Q03164 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
ESR1 P03372 2/20 0.49
ESR2 Q92731 2/20 0.49
KDM4E B2RXH2 2/20 0.49
HPGD P15428 2/20 0.49
GLA P06280 1/20 0.49
GAA P10253 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4054275 0.89 VSIR (0.63) VSIRHDAC3HDAC1HDAC8HDAC6
SCHEMBL4062955 0.89 VSIR (0.56) VSIRHDAC3HDAC1HDAC8HDAC6
SCHEMBL4054281 0.87 NPC1 (0.55) VSIRHDAC3HDAC1HDAC8HDAC6
SCHEMBL4058059 0.87 VSIR (0.61) VSIRHDAC3HDAC1HDAC8HDAC6
SCHEMBL4054584 0.87 NPC1 (0.61) VSIRHDAC3HDAC1HDAC8HDAC6
SCHEMBL4057255 0.86 VSIR (0.58) VSIRHDAC3HDAC1HDAC8HDAC6
SCHEMBL4052730 0.85 VSIR (0.59) VSIRHDAC3HDAC1HDAC8HDAC6
SCHEMBL24295224 0.84 GPR119 (0.62) VSIRGPR119MAPTNPC1RAB9A
SCHEMBL4050496 0.84 VSIR (0.53) VSIRHDAC3HDAC1HDAC8HDAC6
SCHEMBL4060165 0.84 VSIR (0.58) VSIRHDAC6GPR119MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B VSIR 4618/4885HDAC3 813/4885HDAC1 450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.